Last reviewed · How we verify
Sequential PD-1 antibody
Sequential PD-1 antibody works by binding to the PD-1 receptor on T cells, blocking the interaction with its ligands and thereby enhancing the immune response against cancer cells.
Sequential PD-1 antibody works by binding to the PD-1 receptor on T cells, blocking the interaction with its ligands and thereby enhancing the immune response against cancer cells. Used for Metastatic non-small cell lung cancer, PD-L1 positive, Metastatic melanoma.
At a glance
| Generic name | Sequential PD-1 antibody |
|---|---|
| Also known as | Sequential immunotherapy |
| Sponsor | Sun Yat-sen University |
| Drug class | PD-1 inhibitor |
| Target | PD-1 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
This mechanism of action is based on the principle of immune checkpoint inhibition, where the PD-1 receptor is normally used by cancer cells to evade immune detection. By blocking this interaction, the antibody allows the immune system to recognize and attack cancer cells more effectively.
Approved indications
- Metastatic non-small cell lung cancer, PD-L1 positive
- Metastatic melanoma
Common side effects
- Fatigue
- Diarrhea
- Nausea
- Rash
- Pneumonitis
Key clinical trials
- Neoadjuvant Sacituzumab Govitecan Plus Tagitanlimab for Resectable Head and Neck Squamous Cell Carcinoma (PHASE2)
- Cemiplimab Plus Fianlimab for the Treatment of Locally Advanced Head and Neck Basal Cell Carcinoma Before Surgery (PHASE2)
- Carboplatin/Cisplatin + Etoposide + Benmelstobart Sequential Benmelstobart Combined With Anlotinib Versus Carboplatin/Cisplatin + Etoposide + Tislelizumab Sequential Tislelizumab in the Treatment of Extensive Stage Small Cell Lung Cancer (PHASE2)
- A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors (PHASE1)
- Study of DF1001 in Patients With Advanced Solid Tumors (PHASE1, PHASE2)
- Study of Nivolumab and Relatlimab in Advanced Mismatch Repair Deficient Cancers Resistant to Prior PD-(L)1 Inhibitor (PHASE2)
- Combination of High and Low-Dose Radiotherapy With Immune Therapy and TKI in Advanced Colorectal Cancer: A Phase II Study (PHASE2)
- A Study to Evaluate the Safety and Pharmacokinetics of Ceralasertib in Combination With Durvalumab in Chinese Patients With Advanced Solid Tumours (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |